Genta Announces Election of Distinguished Cancer Specialist, Dr. Daniel D. Von Hoff, to Board of Directors

Jan 18, 2000, 00:00 ET from Genta Incorporated

    LEXINGTON, Mass., Jan. 18 /PRNewswire/ -- Genta Incorporated
 (Nasdaq:   GNTA) today announced the election of Dr. Daniel D. Von Hoff, a
 distinguished cancer specialist, to its Board of Directors, effective January
 12, 2000.  Dr. Von Hoff is Professor of Medicine and Director of the
 University of Arizona Cancer Center.  He is also the current President of the
 American Association for Cancer Research (AACR), the world's leading
 scientific organization in this field.
     "I have known Dr. Von Hoff for a number of years, and regard him as the
 world's leading expert in oncology drug development," said Dr. Raymond P.
 Warrell, Jr., Genta's President and CEO.  "I am personally delighted by his
 election to the Board.  Genta will benefit enormously from his unparalleled
 expertise as we enter the pivotal development stages for our lead compound,
 G3139, as well as its successors."
     "Having consulted for Genta in the past," said Dr. Von Hoff, "I am very
 pleased to be advising the company again in this new capacity.  I am very
 familiar with G3139, which represents an exciting and highly innovative
 approach to improve the effectiveness of cancer treatment.   Successful
 development of this agent may prove to be a major advance in patient care, and
 I look forward to assisting Genta in this endeavor."
     Genta is currently conducting clinical studies of G3139 in several types
 of cancer, including malignant melanoma, prostate and breast cancers, and
 non-Hodgkin's lymphoma.  Together with a Cooperative Research and Development
 Agreement (CRADA) with the U.S. National Cancer Institute, Genta has recently
 initiated trials in patients with small cell lung cancer, colo-rectal cancer,
 and acute myelocytic leukemia.  The FDA recently granted Fast Track
 designation for G3139 when used in combination with dacarbazine for treatment
 of patients with advanced malignant melanoma.  In developing its clinical
 program, Genta has focused upon using G3139 in combination with major cancer
 chemotherapeutic compounds, including docetaxel (Taxotere(TM); Aventis),
 paclitaxel (Taxol(TM); Bristol Myers Squibb), irinotecan (Camptosar(TM);
 Pharmacia Upjohn), and other agents.
     G3139 was designed to reduce the Bcl-2 protein level in cancer through an
 "antisense" mechanism that specifically targets the messenger-RNA produced by
 the bcl-2 gene.  In many human cancers, the Bcl-2 protein is believed to be a
 major factor in inhibiting apoptosis, or programmed cell death.  Bcl-2 is
 believed to contribute to both inherent and acquired resistance to treatment
 with anticancer drugs.
     Following is a biography of Dr. Daniel D. Von Hoff M.D.:
     Dr. Von Hoff graduated cum laude from Carroll College and received a M.D.
 from Columbia University College of Physicians and Surgeons.  After internship
 and residency in internal medicine at the University of California, San
 Francisco, he completed a medical oncology fellowship at the National Cancer
 Institute.  Dr. Von Hoff then moved to the University of Texas at San Antonio,
 where he rose to Professor in the Department of Medicine and the Department of
 Cellular and Structural Biology.  In 1999, he became Director of the Cancer
 Center and Professor of Medicine at the University of Arizona.  Among numerous
 awards, he has received the Frederick S. Philips Lectureship from Memorial
 Sloan-Kettering Cancer Center, the Michel Clavel Lectureship from the European
 Organization for Research and Treatment of Cancer (EORTC), and the Bagshawe
 Lectureship from the British Association for Cancer Research.  In 1997, Dr.
 Von Hoff received the Richard and Hilda Rosenthal Foundation Award from AACR
 and was elected President of that organization for 1999-2000.  He has been an
 editor of the journal, Investigational New Drugs, associate editor of Cancer
 Research and Clinical Cancer Research, and has served on the editorial boards
 of the American Journal of Medicine, Anticancer Drugs, Oncology, Annals of
 Oncology, and nine other scientific journals.  He is a Fellow of the American
 College of Physicians, and has been a member of the Board of Directors of the
 American Society of Clinical Oncology (ASCO) and AACR, as well as a member of
 the FDA's Oncology Drug Advisory Committee (ODAC).
     In 1989, Dr. Von Hoff became the Founding Director of the Institute for
 Drug Development at the Cancer Therapy and Research Center in San Antonio.  In
 part, this activity was used to rapidly facilitate the translation of exciting
 laboratory scientific advances into clinical research and patient care.  In
 his positions, he has participated in the early clinical investigations of
 most of the new agents that have been approved for cancer treatment in the
 United States over the past 20 years, including gemcitabine, docetaxel,
 paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, and dexrazoxone.
 He has published more than 450 papers, 120 book chapters, 750 abstracts, and
 several patents, primarily related to studies of new anticancer treatments.
 Dr. Von Hoff has also served as a key scientific advisor to a number of
 pharmaceutical and biotechnology companies.  He is a founder and co-chair of
 the Scientific Advisory Board of Ilex Oncology.
     Genta Incorporated is a biopharmaceutical company whose strategy consists
 of building a product and technology portfolio concentrating on cancer therapy
 including its Anticode(TM) (antisense) products intended to treat cancer at
 its genetic source.  For more detailed information about Genta, please visit
 our web site at .  To receive Genta Incorporated's
 latest news release and other corporate documents via fax, at no cost, dial
 1-800-PRO-INFO; use the Company's symbol GNTA.  Or visit The Financial
 Relations Board's web site at .
     The statements contained in this press release that are not historical are
 forward-looking statements within the meaning of Section 27A of the Securities
 Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
 1934, as amended, including statements regarding the expectations, beliefs,
 intentions or strategies regarding the future.  Without limiting the
 foregoing, the words "anticipates," "believes," "expects," "intends," "may"
 and "plans" and similar expressions are intended to identify forward-looking
 statements.  The Company intends that all forward-looking statements be
 subject to the safe harbor provisions of the Private Securities Litigation
 Reform Act of 1995.  These forward-looking statements reflect the Company's
 views as of the date they are made with respect to future events, but are
 subject to many risks and uncertainties, which could cause the actual results
 of the Company to differ materially from any future results expressed or
 implied by such forward-looking statements.  For example, the results obtained
 in pre-clinical or clinical studies reported above may not be indicative of
 results that will be obtained in future clinical trials; Genta has not
 successfully completed human clinical trials of a product based on antisense
 technology; and delays in the completion of clinical trials as a result of
 delays in patient enrollment or other factors may occur.  Examples of such
 risks and uncertainties also include, but are not limited to: the obtaining of
 sufficient financing to maintain the Company's planned operations; the timely
 development, receipt of necessary regulatory approvals and acceptance of new
 products; the successful application of the Company's technology to produce
 new products; the obtaining of proprietary protection for any such technology
 and products; the impact of competitive products and pricing and reimbursement
 policies; and the changing of market conditions.  The Company does not
 undertake to update forward-looking statements.

SOURCE Genta Incorporated